Dana-Farber’s Breast Oncology Center is leading the #ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer. 📞Call 877-338-7425 or💻visit: dana-farber.org/clinical-trial…

Introducing the newest full Professor at Harvard Medical School, our wonderful colleague and friend Nancy Lin ⁦Nancy Lin, MD⁩! So proud of her for this amazing and well-deserved honor!! ⁦Dana-Farber’s Breast Oncology Center⁩

‌Congratulations to Nancy Lin, MD, (Nancy Lin, MD) Associate Chief of the Division of Breast Oncology Dana-Farber, who has recently been promoted to Professor of Medicine Harvard Medical School!

Congratulations to Adrienne Waks, MD, (Ada Waks) Associate Director, Clinical Research, who has recently been promoted to Senior Physician Dana-Farber!

Congratulations to Leticia Varella, MD, who has recently been promoted to Senior Physician Dana-Farber!

Congratulations to Wendy Chen, MD, MPH, who has recently been promoted to Institute Physician Dana-Farber!

Join Dr Erica Mayer Erica Mayer for an interactive symposium in Chicago! Over dinner & drinks delve into insightful case-based discussions, exploring the expanding role of CDK4/6 inhibitors in #BreastCancer You don't have to be an #ASCO24 registrant to join bit.ly/4aIJX17

#PatientAdvocates attending #ASCO24. Note events, hours, & new location of PA Lounge - S404. Join me, alongside Dr. Erica Mayer (Erica Mayer) & ASCO Clinical Division Director, Pam Mangat: 6/2- 8:00 - 9:00 am CT, to learn about the The Patient-Centered Outcomes Research Institute funded ASCO CDK Dosing Study! #bcsm

Check out our poster (board #147) looking at the predictive value of TILs in pts with TNBC treated with neoadjuvant chemotherapy in TBCRC 030 TILs assessed by pathologists and #AI algorithms were predictive of pathologic response Erica Mayer Dana-Farber’s Breast Oncology Center OncoAlert

Dana-Farber Breast Oncology taking over Chicago! Dana-Farber’s Breast Oncology Center #ASCO24

We are leading a phase 2 trial, called #TRADE, to assess if a brief dose escalation of adjuvant #abemaciclib w/ ongoing endocrine therapy reduces side effects & improves tolerability in patients with early-stage HR-positive and HER2-negative #BreastCancer. dana-farber.org/clinical-trial…

So grateful for our fantastic collaboration and friendship with ABCSG and continued research efforts with Dr. Michael Gnant and Angie DeMichele, MD, MSCE, FASCO

More outstanding talks reviewing the most recent #bcsm data at the Dana-Farber’s Breast Oncology Center OncLive.com summit 👏👏👏 Sara Tolaney Erica Mayer Filipa Lynce, MD, FASCO Antonio Giordano, MD PhD

“I feel like my life is going to flash before my eyes, because this race and this cause has been such an important thing to me for so long,” says Michelle O’Brien. Read more: ms.spr.ly/6011Y7o7f

45th Annual ScientificMeeting of BreastCancerTrials, a marvelous group that sets new standards for clinical breast cancer research. A big ThankYou to Nicholas Zdenkowski and JulietteGritten, meeting international friends including Erica Mayer Hope Rugo AndrewTutt CarlosBarrios ABCSG

Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery for #MaleBreastCancer. For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial…

At Dana-Farber we are dedicated to increasing #DiversityInResearch. Dr. Erica Mayer (Erica Mayer) and Dr. Rachel Freedman (Rachel Freedman, MD, MPH) are leading efforts to improve access to clinical trials and to ensure that research reflects all communities. 👉blog.dana-farber.org/insight/2024/0…

Dana-Farber’s Breast Oncology Center is leading a phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated #BreastCancer. Erica Mayer For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial…

Tina was 33 years old when she was diagnosed with breast cancer. “I’m so grateful Tina came to us so we could help. Now the goal is to get her back on track with life.” – Erica Mayer, MD, Tina’s doctor Donate for Tina: jimmyfund.gives/KCANCER

Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial…